Endocrinology Research, IPSEN, 27 Maple Street, Milford, MA 01757, USA.
Cancer Metastasis Rev. 2011 Mar;30 Suppl 1:9-17. doi: 10.1007/s10555-011-9293-0.
Somatostatin is an important regulator of endocrine and exocrine secretion, affecting the release of many hormones. The effects of somatostatin are mediated through its interaction with one of five somatostatin receptors. Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) express multiple somatostatin receptors, making them excellent potential therapeutic targets. Many trials have shown that treatment with somatostatin analogs is associated with disease stabilization and prolonged survival. More recently, somatostatin analogs have been shown to have antiproliferative effects, thus broadening the scope of their uses. In this review, we update the current data on the treatment of GEP-NETs with somatostatin analogs, with particular emphasis on the results of the PROMID study. In addition, we discuss the current state of knowledge of novel therapies against GEP-NETs, including the use of somatostatin analogs with broader receptor binding profiles, chimeric somatostatin-dopamine molecules, combinations of somatostatin analogs with other active chemotherapy agents, and peptide receptor-targeted radionuclide therapy.
生长抑素是内分泌和外分泌分泌的重要调节剂，影响许多激素的释放。生长抑素的作用是通过与五种生长抑素受体之一的相互作用介导的。胃肠胰神经内分泌肿瘤（GEP-NETs）表达多种生长抑素受体，使其成为极好的潜在治疗靶点。许多试验表明，生长抑素类似物的治疗与疾病稳定和生存延长有关。最近，生长抑素类似物已被证明具有抗增殖作用，从而扩大了其用途的范围。在这篇综述中，我们更新了使用生长抑素类似物治疗 GEP-NETs 的最新数据，特别强调了 PROMID 研究的结果。此外，我们还讨论了针对 GEP-NETs 的新型治疗方法的当前知识状态，包括使用具有更广泛受体结合谱的生长抑素类似物、嵌合生长抑素-多巴胺分子、生长抑素类似物与其他活性化疗药物的联合应用以及肽受体靶向放射性核素治疗。
